Navigation Links
Study Validates Clinical Accuracy of 50% Dose Reduction for Positron Emission Mammography
Date:6/7/2011

sented results of a study to detect lesions with very low doses of radiation using the Naviscan high-resolution PET scanner.  Preliminary results from five patients with invasive ductal carcinoma as well as phantom images show that PEM lesion detection at a 5 mCi injected dose of FDG, or 50% lower than the dose commonly used in clinical practice, yielded comparable sensitivity while maintaining lesion detectability.  Preliminary results also revealed that injected dose could be reduced further for lighter patients or with concordant increased scan time. These results are part of an ongoing clinical trial at Swedish Medical Center with the goal of determining the lowest optimized dose levels of FDG required to produce high quality PEM images in patients with breast cancer.

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com.

For more information, including images, videos, quotes and links, please visit the social media news release (SMNR) at http://pitch.pe/151545.


'/>"/>
SOURCE Naviscan, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New Study Finds Patient Adherence to Statin Medications Reduces Hospitalizations and Healthcare Costs
2. Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx® in Directing Chemotherapy in Gynecological Cancers
3. New Study Released Today Showed Patients With Deadly Form of Lung Cancer Lived Longer Without Disease Worsening
4. Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy
5. New Study Questions Ability of Radiology Benefit Managers to Lower Costs
6. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
7. Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization
8. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
9. Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment
10. All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
11. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... VIEJO, Calif., Oct. 12, 2011 Avanir Pharmaceuticals, Inc. ... affect (PBA) prevalence data from stroke survivors will be ... Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine in ... details about the data presentation at ACRM/ASNR Progress ...
... Good Start Genetics,™ Inc., an innovative molecular diagnostics ... screening, today announced that it will present results ... next-generation DNA sequencing platform at the Annual Meeting ...  ASRM will be held from October 15-19, 2011 ...
Cached Medicine Technology:Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference 2Good Start Genetics to Announce Validation Study Results for its Next-Generation DNA Sequencing Platform During an Oral Presentation at the 2011 Annual Meeting of the American Society for Reproductive Medicine (ASRM) 2
(Date:4/23/2014)... Center researchers say clinical trials for a new ... are very promising. Patients treated with CPX-351, a ... are showing better responses than patients treated with ... "Acute myeloid leukemia is an aggressive blood cancer ... in older patients," explained Jeffrey Lancet, M.D., senior ...
(Date:4/23/2014)... to high-energy particles, simulating conditions astronauts would face on ... and slower reaction times, even when the radiation exposure ... impairments which affected a large subset, but far ... linked to protein changes in the brain, the scientists ... humans, suggest it may be possible to develop a ...
(Date:4/23/2014)... falls below normal levels are more likely to have ... disease and type 2 diabetes. A new simple screening ... and possible treatment is described in an article in ... from Mary Ann Liebert, Inc., publishers. The article is ... website at http://www.liebertpub.com/jmh . , ...
(Date:4/23/2014)... often displayed in the popular Swedish children,s TV ... high-sugar foods. A new study from the University ... children,s TV programmes as well as the link ... weight status. , Steingerdur Olafsdottir,s doctoral thesis focuses ... Swedish children,s TV show Bolibompa. Healthy foods dominated ...
(Date:4/23/2014)... of Midlife Occupational and Leisure Time Physical Activity on ... activity in midlife increases the risk of mobility limitation ... risk. This is found in a study which followed ... study was conducted at the Gerontology Research Center in ... Heavy physical labor is often repetitive, wears the body ...
Breaking Medicine News(10 mins):Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 2Health News:Some astronauts at risk for cognitive impairment, animal studies suggest 3Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... half their concerns, so doctors should listen carefully, ... -- Older patients and surgeons don,t communicate effectively ... decision to have surgery can be particularly difficult ... School of Medicine study. , The researchers recorded ...
... Air-Pulse Autonomic Meditation Therapy is a non-denominational therapy that allows ... identity many feel when adopting ancient mind controlling meditative healings. ... ... 14, 2008 –- Dr. Ajrawat,s http://www.painmanagement.com/ [Air-Pulse Autonomic ...
... childhood asthma, but, when compared to girls, they are also ... have a decreased incidence of asthma in the post-pubertal years. ... asthma development, according to a prospective study that analyzed airway ... moderate asthma over a period of about nine years. , ...
... the past two decades, medication errors have dramatically increased. DecisionHealth, ... potentially harmful medication errors. , ... Gaithersburg, MD (PRWEB) ... Health Ledger,s recent drug overdose, increased dramatically over the past two ...
... Investigators from the Melbourne Center of the international Ludwig Institute ... reported that they have developed a test to predict whether ... metastatic Stage IV cancer and death. , More than ... has spread to the lymph nodes will typically have ...
... Investment to Close in September, Subject to Stockholder ... Potential Launch of MOXATAG(TM), GERMANTOWN, Md., Aug. ... a pharmaceutical company focused on,developing and commercializing novel ... the quarter ended June 30,2008., MiddleBrook reported ...
Cached Medicine News:Health News:Older Adults Reluctant to Question Surgical Treatment 2Health News:Dr. Ajrawat's Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark 2Health News:Dr. Ajrawat's Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark 3Health News:Dr. Ajrawat's Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark 4Health News:Dr. Ajrawat's Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark 5Health News:Asthma in boys may be just a phase, but for girls it may be there to stay 2Health News:Fatalities From Medication Errors at Home Up Dramatically - DecisionHealth Offers Solutions 2Health News:Fatalities From Medication Errors at Home Up Dramatically - DecisionHealth Offers Solutions 3Health News:Prototype test for predicting clinical outcome for melanoma patients 2Health News:Prototype test for predicting clinical outcome for melanoma patients 3Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 2Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 3Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 4Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 5Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 6Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 7Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 8Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 9Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 10Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 11Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 12Health News:MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results 13
Infusion Cannula, 2.0mm....
Subretinal Fluid Cannula, Curved; 20g (0.90) x 1-1/2" (38mm); 12mm Flexible Tubing Extends 6mm Beyond Tip; Curved at 65°....
Micro Vitreoretinal Cannula; Angled; 20g (0.90) x 1" (25mm); Tip Extension: 3mm, 32g (0.23); Angled at 65°, 1mm from Tip....
...
Medicine Products: